Join A/Prof Karin Reid who will discuss how Circulating-Tumour-Cells (CTC) are biomarkers for early cancer development and treatment effectiveness and that early detection CTC screening is suggested for patients with higher risk of malignancy, e.g. smoking, family history, long-term oral contraception or hormone-replacement-therapy (HRT), or age over 50 years.

  • Webinar
  • 11 Sep 2019
  • 5:30pm-6:30 AEST
  • 1

Karin will outline how the cytology-based Blood Test is a screening tool, which can identify the presence, number and type of Circulating-Tumour-Cells (CTC), atypical inflammatory cells, and other rare cells including infectious agents.

About the presenter:

A/Prof Dr Karin Ried is Director of Research at the National Institute of Integrative Medicine (NIIM), Melbourne, Victoria. A/Prof Ried is Honorary Adjunct Assistant Professor, Bond University, Queensland, and Honorary Visiting Research Fellow at The University of Adelaide, South Australia. 

A/Prof Ried has 20 years' experience in medical and public health research, and research interest in complementary and integrative medicine with a focus on nutritional health and integrative therapies. 

Her current research projects encompass nutritional medicine, cardiovascular and brain health, chronic diseases and cancer.